Canada's Drug Agency has just released brand new guidance on the use of surrogate endpoints in HTAs. The recommendations cover definitions, justification, adoption, statistical validation, models, reporting, and quantifying & presenting uncertainty. Find out more at www.cda-amc.ca/methods-and-...